66 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
substantial harm. There can be no assurance that we will resolve any adverse event related to any of our products to the satisfaction of the FDA or any … be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities that our product candidates are safe and effective
S-8
EX-5.1
CRBU
Caribou Biosciences Inc
11 Mar 24
Registration of securities for employees
5:08pm
of originals or copies certified or otherwise identified to our satisfaction as being true reproductions of originals, of all such documents, records
8-K
EX-99.2
9r997e5zfp
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
8-K
EX-99.1
heamc
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
8-K
z6e4og ferj6ixw64m02
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
8-K
EX-5.1
sj7hh trf
14 Jul 23
Caribou Biosciences Announces Proposed Public Offering of Common Stock
6:33pm
424B5
fapfqs9zwh2k 0lhs
14 Jul 23
Prospectus supplement for primary offering
5:31pm
424B5
ann7d3iwkr
13 Jul 23
Prospectus supplement for primary offering
4:56pm
8-K
EX-10.1
vcfejivnc5j7r3t19sm
6 Jul 23
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
8:01am
ARS
mycpa2ed uw23rzv48d5
28 Apr 23
Annual report to shareholders
12:00am
DEF 14A
99b hxsf3bij0knsa
11 Aug 22
Definitive proxy
4:04pm